The Cooper Companies, Inc. Common Stock COO

The Cooper Companies, Inc. es una empresa global de dispositivos médicos. La compañía opera a través de dos segmentos: CooperVision y CooperSurgical. El segmento de CooperVision se dedica al desarrollo, fabricación y comercialización de una variedad de productos para usuarios de lentes de contacto, con materiales y ópticas avanzadas. CooperVision diseña sus productos para resolver desafíos de visión como astigmatismo, presbicia, miopía, sequedad ocular y fatiga visual, con una colección de lentes de contacto esféricas, tóricas y multifocales. El segmento de CooperSurgical se enfoca en mejorar la salud de mujeres, bebés y familias a través de un portafolio diversificado de productos y servicios que incluyen dispositivos médicos, fertilidad, diagnósticos y anticoncepción. Los productos de CooperSurgical se utilizan en consultorios médicos y procedimientos quirúrgicos, principalmente por obstetras/ginecólogos (OB/GYN); y productos/equipos de fertilidad y servicios de pruebas genéticas utilizados principalmente en clínicas de fertilidad y laboratorios.

COO hizo una división de acciones (split) de 4:1 el 20 de febrero de 2024: cada acción se convirtió en 4. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 5 oct

  Securities Fraud Investigation Into The Cooper Companies, Inc. (COO) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  The Cooper Companies faces a securities fraud investigation following disappointing Q3 2026 results. The company reported flat year-over-year revenue of $717 million, attributed to U.S. channel inventory reductions. Cooper lowered full-year guidance by approximately 1.4% in revenue and 1.8% in EPS, causing shares to decline 14.67% on September 10, 2026.

  

• The Motley Fool 2 oct

  Cooper Companies Director Kurzius Buys $549,300 in Shares. Is the Eye Care Stock About to Rally?

  Lawrence Erik Kurzius, a Director at Cooper Companies, purchased 10,000 shares worth $549,300 at $54.93 per share on September 16, 2026, increasing his total holdings to 31,099 shares. The insider buy signals confidence in the company's recovery prospects following a 16% stock decline over the past year. The article notes that insider purchases typically predict higher share prices within 30 days and suggest management believes in the company's long-term growth, particularly after deciding to retain its surgical unit rather than divest it.

  

• GlobeNewswire Inc. 25 sept

  The Cooper Companies, Inc. Investor News: If You Have Suffered Losses in The Cooper Companies, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

  Rosen Law Firm has announced an investigation into potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) for allegedly issuing materially misleading business information. The investigation was triggered by CooperCompanies' disappointing earnings report on September 10, 2026, which included weak guidance and a decision not to sell CooperSurgical, causing the stock to fall 14.6%. Investors who purchased CooperCompanies securities may be eligible for compensation through a class action lawsuit.

  

• GlobeNewswire Inc. 15 sept

  COOPER COMPANIES, INC. INVESTIGATION: COO Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

  Law firm Kirby McInerney LLP is investigating potential securities law violations by Cooper Companies following the company's September 9, 2026 earnings announcement. CooperCompanies reported Q3 revenue of $1.07 billion, missing analyst expectations of $1.10 billion, with its CooperVision segment showing flat year-over-year growth. The company attributed underperformance to proactive U.S. channel inventory reductions. The stock declined 14.7% on the news, falling from $63.48 to $54.17 per share.

  

• Zacks Investment Research 14 sept

  International Markets and The Cooper Companies (COO): A Deep Dive for Investors

  The Cooper Companies reported Q3 2026 total revenue of $1.07 billion with minimal 0.6% year-over-year growth. EMEA contributed 29% of revenue ($309.4M), beating analyst expectations by 1.93%, while Asia Pacific generated $126M (11.8%), missing projections by 6.14%. The company faces headwinds from currency fluctuations and geopolitical risks. COO received a Zacks Rank #5 (Strong Sell) rating and has underperformed the market significantly, declining 29.2% over the past month compared to the S&P 500's 0.8% decline.